Sage Journals: Discover world-class research

Abstract

Multidrug resistant (MDR) bacterial infections are a major concern of health care providers due to their increasing incidence and associated mortality. In some cases, few or no antibiotics have preserved activity. Beta-lactam administration via continuous infusion can optimize time over minimum inhibitory concentration (MIC). In some cases, use of high-dose continuous infusion (HDCI) may be necessary to achieve serum levels in excess of nonsusceptible MIC values. The use of HDCI beta-lactams is not without risk, specifically neurotoxic adverse effects, which appear dose related. We describe a 64-year-old male who experienced myoclonus and nonconvulsive status epilepticus while receiving HDCI ceftazidime for treatment of multidrug resistant Pseudomonas aeruginosa bacteremia. This report serves as a cautionary example of the potential toxicities associated with HDCI beta-lactams and supports the importance of risk–benefit analysis prior to and during treatment. Additionally, the use of serum drug level monitoring may be necessary to better prevent or predict toxicity.

Keywords

seizures cephalosporins adverse drug reactions drug administration bacterial infections

Get full access to this article

View all access options for this article.

References

Nicasio

Kuti

Nicolau

. The current state of multidrug-resistant gram-negative bacilli in North America. Pharmacotherapy. 2008;28(2):235–249.

Lodise

Lomaestro

Drusano

. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2006;26(9):1320–1332.

Moriyama

Henning

Childs

. High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients. Ann Pharmacother. 2010;44(5):929–935.

Grill

Maganti

. Neurotoxic effects associated with antibiotic use: management considerations. Br J Clin Pharmacol. 2011;72(3):381–393.

Chow

Hui

Szeto

. Neurotoxicity induced by beta-lactam antibiotics: from bench to bedside. Eur J Clin Microbiol Infect Dis. 2005;24(10):649–653.

Chow

Szeto

Hui

. Retrospective review of neurotoxicity induced by cefepime and ceftazidime. Pharmacotherapy. 2003;23(3):369–373.

Grill

Maganti

. Cephalosporin-induced neurotoxicity: clinical manifestations, potential pathogenic mechanisms, and the role of electroencephalographic monitoring. Ann Pharmacother. 2008;42(12):1843–1850.

Martinez-Rodriguez

Barriga

Santamaria

. Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure. Am J Med. 2001;111(2):115–119.

Klion

Kallsen

Cowl

. Ceftazidime-related nonconvulsive status epilepticus. Arch Intern Med. 1994;154(5):586–589.

10.

Jackson

Berkovic

. Ceftazidime encephalopathy: absence status and toxic hallucinations. J Neurol Neurosurg Psychiatry. 1992;55(4):333–334.

11.

Chow

Wang

Hui

. Nonconvulsive status epilepticus in peritoneal dialysis patients. Am J Kidney Dis. 2001;38(2):400–405.

12.

Slaker

Danielson

. Neurotoxicity associated with ceftazidime therapy in geriatric patients with renal dysfunction. Pharmacotherapy. 1991;11(4):351–352.

13.

Mouton

den Hollander

. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 1994;38(5):931–936.

14.

Tessier

Nicolau

Onyeji

. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model. Chemotherapy. 1999;45(4):284–295.

15.

Robaux

Dube

Caillon

. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model. J Antimicrob Chemother. 2001;47(5):617–622.

16.

Navas

Caillon

Gras-Le Guen

. Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas aeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics. J Antimicrob Chemother. 2004;54(4):767–771.

17.

Moriyama

Henning

Neuhauser

. Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria. Ann Pharmacother. 2009;43(7):1324–1337.

18.

Little

Kerrigan

McDougall

. Nonconvulsive status epilepticus in patients suffering spontaneous subarachnoid hemorrhage. J Neurosurg. 2007;106(5):805–811.

19.

Claassen

Mayer

Kowalski

. Detection of electrographic seizures with continuous EEG monitoring in critically ill patients. Neurology. 2004;62(10):1743–1748.

20.

Dennis

Claassen

Hirsch

. Nonconvulsive status epilepticus after subarachnoid hemorrhage. Neurosurgery. 2002;51(5):1136–1143; discussion 1144.

21.

Falagas

Kasiakou

. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006;10(1): R27.

22.

Spapen

Jacobs

Van Gorp

. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care. 2011;1(1):14.

23.

Naranjo

Busto

Sellers

. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245.

Probable Nonconvulsive Status Epilepticus With the Use of High-Dose Continuous Infusion Ceftazidime

Abstract

Keywords

Get full access to this article

References